STAB.US Statera Biopharma Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 17, 2026
0.0001 0.0266
Market cap
USD 7.14K
P/E
-
P/B
0.16x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is STAB.US undervalued?

Graham number

The Graham number of Statera Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Statera Biopharma Inc fundamental analysis

No fundamental analysis for Statera Biopharma Inc yet.

Statera Biopharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Statera Biopharma Inc

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, i…

Full company profile